Quantcast

Latest Pre-exposure prophylaxis Stories

2010-11-23 13:28:42

Successful trial provides proof of concept for oral use of antiretrovirals in preventing HIV infections in men who have sex with men CONRAD is pleased to join in congratulating the Global iPrEx study team for their successful trial of oral tenofovir (TDF) with emtricitabine (FTC) for HIV prevention. Results of the National Institutes of Health (NIH) sponsored study were announced today in the New England Journal of Medicine. Daily use of the widely used antiretroviral combination pill was...

2010-11-23 13:25:54

Major study published in the New England Journal of Medicine demonstrates the effectiveness of a new HIV prevention tool, pre-exposure prophylaxis (PrEP) In a finding with the potential to fundamentally change strategies to slow the global HIV epidemic, a new study called iPrEx shows that individuals at high risk for HIV infection who took a single daily tablet containing two widely used HIV medications, emtricitabine and tenofovir (FTC/TDF), experienced an average of 43.8% fewer HIV...

2010-11-23 13:00:23

NIH's NIAID-sponsored Study Finds Pre-exposure Prophylaxis Concept Effective Among Men who Have Sex with Men A daily dose of an oral antiretroviral drug, currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. The findings, a major advance in HIV prevention research, come from a large international clinical trial published online Nov. 23 by the New England Journal of Medicine. The study, titled "Chemoprophylaxis...

2010-11-23 12:49:18

The results of the iPrEx PrEP effectiveness trial of once-daily TDF/FTC (brand name Truvada) in gay men, transgender women and other men who have sex with men are a landmark in HIV prevention research. The results, released on November 23, showed that TDF/FTC reduced risk of HIV infection by an average of 43.8%. This was calculated by looking at rates of infections among participants who received TDF/FTC plus a standard prevention package compared to those in the placebo arm who received a...

2010-11-23 12:36:48

VOICE Study in women more important than ever In a significant advance for HIV prevention research, a clinical trial confirms that the same drugs used for treating HIV can also help prevent HIV infection in the first place. The study, known as iPrEx, is important because it gives credence to an HIV prevention approach called oral pre-exposure prophylaxis (PrEP), which involves the use of antiretrovirals (ARVs) by people who are HIV-negative and at high risk of infection. It is the first of...

2010-11-23 12:33:31

Data suggest need for rectal gel option Results of the world's first efficacy trial of an HIV-prevention approach called oral pre-exposure prophylaxis, or PrEP, were released online in the New England Journal of Medicine today. Data from this trial, called iPrEx, indicated an estimated 43.8% reduction of new HIV infections among men who took an antiretroviral tablet daily to prevent HIV, compared to those who took a placebo pill. "This discovery alters the HIV prevention landscape forever....

2010-11-23 07:05:00

Public health agencies and communities must move quickly to translate trial results into impact NEW YORK, Nov. 23, 2010 /PRNewswire-USNewswire/ -- "This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention by HIV-negative people at high risk for HIV infection," said AVAC Executive Director Mitchell Warren....

2010-11-23 07:05:00

SEATTLE, Nov. 23, 2010 /PRNewswire/ -- Congratulations to the investigators and staff who conducted iPrEx, a rigorous trial of HIV prevention by administration of daily anti-retroviral medicine to men at high risk of HIV infection. This was a well-designed and well-executed trial that has demonstrated that HIV may be prevented through this type of biomedical intervention. Pre-exposure prophylaxis (PrEP) is an exciting addition to the "toolbox" of HIV prevention strategies. Information...

2010-11-23 07:01:00

JOHANNESBURG and WASHINGTON, Nov. 23, 2010 /PRNewswire-USNewswire/ -- The Global Campaign for Microbicides (GCM) welcomes today's news from the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Disease (NIAID) of the US National Institutes of Health (NIH) and the Gladstone Institutes of the University of California, San Francisco that daily use of oral emtricitabine (FTC) with tenofovir (TDF) in one tablet shows promise to safely and effectively help to prevent...

2010-09-03 12:14:00

NEW YORK, Sept. 3 /PRNewswire-USNewswire/ -- AVAC today issues a call to action to donors, policy-makers, researchers and advocates to ensure that critical follow-up studies to the landmark CAPRISA 004 microbicide trial receive the economic and political support needed to move forward as quickly as possible. The call comes as a group of microbicide and public health experts have agreed upon a plan for further studies, which are expected to cost $100 million over three years, of which only...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related